Bone age progression during five years of substitutive therapy for the induction of puberty in thalassemic girls - Effects on height and sitting height

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 4, 1999, Pages 525-530

  Filosa, Aldo ^a,d   Di Maio, S ^b   Lamba, M ^a   Baron, I ^a   Saviano, A ^a   Esposito, G ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d NONE   (Italy)

Author keywords

Body disproportion; Estrogens; Hypogonadism; Thalassemia

Indexed keywords

ESTROGEN;

ADOLESCENT; ADULT; AGE; ARTICLE; BETA THALASSEMIA; BODY HEIGHT; BONE AGE; BONE MATURATION; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; PUBERTY; SITTING;

EID: 0032767311     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.4.525     Document Type: Article

References (29)

1. Old JM, Higgs DR. Gene analysis. In: Weatherall DJ, ed. Methods in Haematology. The Thalassemias. Edinburgh: Churchill Livingstone, 1982; 74-102.
2. Old JM, Varawalla NJ, Weatherall DJ. Rapid detection and prenatal diagnosis of β-thalassemia. Lancet 1990; 336: 834-837.
3. Piomelli S. The management of patients with Cooley's anaemia: Transfusions and splenectomy. Semin Haematol 1995; 32: 262-268.
4. Wolman I. Transfusion therapy in Cooley's anaemia: growth and health as related to long range haemoglobin level. Ann NY Acad Sci 1964; 119: 736-747.
5. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997; 86: 342-346.
6. Grundy RG, Woods KA, Savage MO, Evans J. Relationship of endocrinopathy to iron chelation status in young patients with thalassemia major. Arch Dis Child 1994; 71: 128-133.
7. Italian Working Group on Endocrine Complications in Non-Endocrine Disease. Multicentre study on prevalence of endocrine complications in thalassemia major. Clinl Endocrinol 1995; 42: 581-586,
8. De Virgilis S, Congia M, Frau F. Desferoxamine-induced growth retardation in patients with thalassemia major. J Paediatr 1988; 113: 661-669.
9. Olivieri NF, Weatherall DJ. Recent progress in the managment of thalassemia. Hong Kong J Pediatr 1996; 1: 1-10.
10. Porter JB, Jaswon MS, Huhens ER, East CA, Jonathan WP. Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403-409.
11. Benso L, Pastorin L, Gambotto S, Petri A, Gianino P, Signorile F, Gabutti V. Auxological study of the onset of puberty and of the age at menarche in β thalassemic patients. Acta Med Auxol 1990; 22: 51-56.
12. De Sanctis V, Ughi M, Pinamonti A, Zachmann M, Torresani T, Gamberini R, Di Plama A, Bagni B, Cavallini AR, Vullo C. Growth retardation in thalassemia major. In: Prader A, Rappaport R, eds. Clinical Issues in Growth Disorders: Evaluation, Diagnosis and Therapy. Tel Aviv-London: Freund Publishing House Ltd, 1994; 31-47.
13. Aldouri MA, Wonke B, Dandona P, Flynn DM, Hoffbrand AV. Clinical, biochemical and radiological bone changes in secondary amenorrhea. In: La Maturazione Sessuale Nella β-Thalassemia Major. Meeting Internazionale, Ferrara, 1986.
14. Cistemino M, Bozzola M, Chiara A, Biscaldi I, Squillaciotti F, Grignani G, Perani G, Roger M. Transdermal estradiol substitution therapy for female hypogonadism in thalassemia major. Adolesc Pediatr Gynecol 1990; 3: 25-30.
15. Largo KH, Prader A. Pubertal development in Swiss girls. Helv Paediatr Acta 1983; 38: 229-243.
16. Greulich WW, Pyle S. Radiographic Atlas of the Skeletal Development of Hand and Wrist, 2nd Ed. Stanford, CA: Stanford University Press, 1959.
17. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity. British children. Arch Dis Child 1966; 41: 454-468.
18. Tanner JM. Physical growth and development. In: Forfar JO, Arneil GC, eds. Textbook of Paediatrics. Edinburgh: Churchill Livingstone, 1987; 253-303.
19. Tanner JM, Whitehouse RH. Sitting Height Charts. Herts, UK: Castelmead, 1987.
20. Frank GR. The role of oestrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatr 1995; 84: 627-630.
21. Pasquino AM, Pucarelli I, Passeri F, Segni M, Mancini MA, Municchi G. Progression and premature thelarche to central precocious puberty. J Paediatr 1995; 126: 11-14.
22. Du-Caju MV, Bleyaert S, Op De Beeck L. Growth inhibition using oestrogens in constitutionally tall girls. Acta Clin Belg 1993; 48: 11-19.
23. Schmitt K, Schilling R, Frisch H, Schober E, Weninger M, Tulzer G, Waldhauser F. Reduction of body height in tall girls by oestrogen treatment. Klin Pädiatr 1992; 2046: 405-410.
24. Svan H, Ritzen EM, Hall K, Johansson L. Oestrogen treatment of tall girls: dose dependency of effects on subsequent growth and IGF-I levels in blood. Acta Paediatr Scand 1991; 80: 328-333.
25. 3 syndrome in thalassemia major. Arch Dis Child 1983; 58: 120-127.
26. Filosa A, Giani U. Periodical model of haematopoiesis in thalassemic people. In: Beuzard Y, Lubin B, Rosa J, eds. Sickle Cell Disease and Thalassemias: New Trends in Therapy. Paris: John Libbey Eurotex, Les Editions INSERM, 1994; 320-322.
27. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J, New M, Hilgartner MW. Abnormal bone metabolism in thalassemia. In: Andò S, Brancati C, eds. Endocrine Disorders in Thalassemia. Physiopathological and Therapeutical Aspects. Berlin: Springer Verlag, 1995; 39-46.
28. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassemia major patients with severe bone lesions due to desferoxamine. Eur J Pediatr 1996; 155: 368-372.
29. Low LCK. Growth, puberty and endocrine function in beta-thalassemia major. J Pediatr Endocrinol Metab 1997; 10: 175-184.